Invitation to the presentation of Calliditas´s interim report January - March 2024

Rhea-AI Summary

Calliditas Therapeutics announced the release of its interim report for Q1 2024 on May 23, 2024, at 07:00 CET. The company will hold a combined audio cast and telephone conference at 14:30 CET the same day, featuring CEO Renée Aguiar-Lucander, CFO Fredrik Johansson, CMO Richard Philipson, and President North America Maria Törnsén. Stakeholders can participate via a webcast or register for the conference call to ask questions. The presentation will be in English, and further details can be obtained from Calliditas's Head of IR & Sustainability, Åsa Hillsten.

Positive

• Announcement of Q1 2024 interim report release date enhances transparency.
• Opportunity for stakeholders to ask questions during the conference call.
• Involvement of key executives in the presentation indicates comprehensive coverage.

Negative

• No specific financial or clinical data provided in the press release.
• Potential investor uncertainty due to the lack of preliminary performance indicators.

STOCKHOLM, May 16, 2024 /PRNewswire/ -- Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET.

A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén.

The presentation will be given in English.

Link to the webcast: 

Calliditas Therapeutics Q1 Report 2024 (financialhearings.com)

To participate via conference call please register via this link: https://conference.financialhearings.com/teleconference/?id=50047214

After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity to ask oral questions.

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel. +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information was sent for publication, through the agency of the contact person set out above, on 16 May, 2024, at 8:30 a.m. CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/invitation-to-the-presentation-of-calliditas-s-interim-report-january---march-2024,c3982567

The following files are available for download:

https://mb.cision.com/Main/16574/3982567/2801057.pdf

Invitation to the presentation of Calliditas_Q1 2024

 

View original content:https://www.prnewswire.com/news-releases/invitation-to-the-presentation-of-calliditass-interim-report-january--march-2024-302147351.html

SOURCE Calliditas Therapeutics

FAQ

When will Calliditas release its Q1 2024 interim report?

Calliditas will release its Q1 2024 interim report on May 23, 2024, at 07:00 CET.

How can I participate in Calliditas's Q1 2024 interim report presentation?

You can participate via a webcast or by registering for the telephone conference.

Who will be presenting Calliditas's Q1 2024 interim report?

The presentation will feature CEO Renée Aguiar-Lucander, CFO Fredrik Johansson, CMO Richard Philipson, and President North America Maria Törnsén.

What time is the Calliditas Q1 2024 interim report presentation?

The presentation is scheduled for May 23, 2024, at 14:30 CET.

Will the Calliditas Q1 2024 interim report presentation be available in English?

Yes, the presentation will be given in English.